Factors influencing insulin requirements in using continuous subcutaneous insulin infusion or multiple daily injections in type 2 diabetes

Table 1 Patients’ characteristics, mean ± SD/n (%)

Factors	MDI therapy (n = 561)	CSII therapy (n = 393)
Age in years, median (interquartile)	57.0 (49.0, 65.0)	56.0 (48.5, 64.0)
Sex
Men	351 (58.5)	235 (56.6)
Women	249 (41.5)	180 (43.4)
Duration of diabetes in years, median (interquartile)	10.0 (5.0, 15.0)	9.0 (3.0, 13.5)b
BMI in kg/m2, median (interquartile)	23.7 (21.7, 26.0)	24.9 (23.0, 27.0)b
WC in cm	87.7 ± 10.0	90.0 (85.0, 96.0)b
FPG in mmol/L, median (interquartile)	8.6 (6.8, 10.8)	8.3 (6.4, 10.6)
HbA1c as %, median (interquartile)	9.7 (7.8, 11.3)	9.5 (7.9, 11.0)
Fasting C-peptide in nmol/L, median (interquartile)	302.0 (180.7, 483.7)	324.3 (217.6, 468.9)
2 hour-postprandial C-peptide in nmol/L, median (interquartile)	577.4 (305.0, 1051.3)	609.9 (389.6, 1003.3)
Total cholesterol in mmol/L, median (interquartile)	4.0 (3.6, 5.1)	4.1 (3.6, 5.2)
LDL cholesterol in mmol/L, median (interquartile)	3.3 (2.4, 3.4)	3.4 (2.6, 3.5)
HDL cholesterol in mmol/L, median (interquartile)	1.0 (0.8, 1.4)	1.0 (0.8, 1.3)
Triglycerides in mmol/L, median (interquartile)	1.7 (1.3, 2.2)	1.7 (1.4, 2.3)

^bP < 0.01.

BMI: Body mass index; CSII: Continuous subcutaneous insulin infusion; MDIs: Multiple daily injections; WC: Waist circumference; FPG: Fasting plasma glucose; HbA1c: Glycated hemoglobin; HDL cholesterol: High-density lipoprotein cholesterol; LDL cholesterol: Low-density lipoprotein cholesterol.